tirzepatide and sleep for the Treatment of Obstructive Apnea Obesity FDA Approves Tirzepatide (Zepbound) as

In December 2025, the Trump administration announced the BALANCE Model a new federal program that could expand access to GLP-1s through both Medicare and Medicaid beginning as early as May 2026

It uses immunosuppressive chemotherapy to remove the immune cells that produce the anti-receptor antibodies, then reinfuses the patients own stored stem cells to rebuild an immune system that no longer attacks the neuromuscular junction

However, there are some differences in side effect patterns

Eli Lilly has not yet filed an NDA

Neuropharmacology (2020) 170:108042

This is important news because it means these medications can help a wide range of patients achieve their health goals